Pharmacopeia (Nasdaq:
PCOP), an innovator in the discovery and development of novel small
molecule therapeutics, announced that PS433540, its first-in-class
Dual Acting Receptor Antagonist (DARA), showed statistically significant
blood pressure reductions in a Phase 2a study in patients with mild to
moderate hypertension. PS433540 is being developed as a potential treatment
for both hypertension and diabetic nephropathy and is a novel blood
pressure product candidate that possesses two validated mechanisms of
action in a single molecule. The data will be presented today at the Recent
and Late Breaking Clinical Trials Session at the American Society of
Hypertension (ASH) Twenty-Third Annual Scientific Meeting and Exposition in
Buy ultram pills New Orleans.
The Phase 2a study met its primary endpoint by showing a statistically
significant reduction in mean 24-hour systolic ambulatory blood pressure
over placebo. The study also showed statistically significant improvements
over placebo in mean 24-hour diastolic ambulatory blood pressure as well as
seated blood pressure. In this double-blind, placebo-controlled study,
patients treated with 200 mg of PS433540 once daily experienced a 12/9mmHg
drop in mean 24-hour systolic and diastolic blood pressure and those
treated with 500 mg experienced a 15/10mmHg drop in mean 24-hour systolic
and diastolic blood pressure. These reductions were highly statistically
significant vs. placebo (PBuy levitra without prescription | Buy ultram without prescription | generic propecia online buy